NASDAQ:GNVC - GenVec Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.19
+0.30 (1.20%)
Get New GenVec Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNVC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNVC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for GenVec in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.19.

This chart shows the closing price for GNVC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in GenVec. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/25/2017HC WainwrightDowngradeHold$7.00N/A
1/25/2017Rodman & RenshawDowngradeBuy ➝ Neutral$15.00 ➝ $7.00N/A
(Data available from 12/9/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
GenVec logo
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Read More

Today's Range

Now: $7.19
Low: $7.19
High: $7.19

50 Day Range

MA: N/A

52 Week Range

Now: $7.19
Low: $2.70
High: $10.44

Volume

N/A

Average Volume

259,136 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of GenVec?

The following sell-side analysts have issued stock ratings on GenVec in the last year:
View the latest analyst ratings for GNVC.

What is the current price target for GenVec?

0 Wall Street analysts have set twelve-month price targets for GenVec in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for GenVec in the next year.
View the latest price targets for GNVC.

What is the current consensus analyst rating for GenVec?

GenVec currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GNVC.

How do I contact GenVec's investor relations team?

GenVec's physical mailing address is 910 Clopper Rd Ste 220n, GAITHERSBURG, MD 20878-1353, United States. The biopharmaceutical company's listed phone number is +1-240-6320740. The official website for GenVec is www.genvec.com.